Koss-Olinger Consulting’s Co-Diagnostics CODX Stock Holding History

Koss-Olinger Consulting’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,937	Closed	-$44K	–	312
2024 Q4	$44K	Hold	1,937	–	–	﹤0.01%	181
2024 Q3	$73K	Sell	1,937 -26	-1%	-$998	0.01%	268
2024 Q2	$74K	Buy	+1,963	New	+$71.4K	0.01%	257
2024 Q1	–	Sell	-1,958	Closed	-$78K	–	100
2023 Q4	$78K	Sell	1,958 -1,769	-47%	-$62.4K	0.01%	307
2023 Q3	$119K	Buy	3,727 +1,558	+72%	+$58.9K	0.02%	263
2023 Q2	$72K	Buy	2,169 +1,119	+107%	+$42.8K	0.01%	276
2023 Q1	$47K	Buy	1,050 +171	+19%	+$13.7K	0.01%	258
2022 Q4	$66K	Buy	+879	New	+$82.3K	0.01%	234

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAG

Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Koss-Olinger Consulting's CODX Position: Q1 2025 in Review

Koss-Olinger Consulting sold out of Co-Diagnostics (CODX) in Q1 2025, closing a stake of 1,937 shares — an estimated $44K sold.

Koss-Olinger Consulting first reported a position in CODX in Q4 2022 and held it in 8 quarters. The position peaked at $119K in Q3 2023. 38 funds tracked by Wall St. Rank hold CODX as of Q1 2025.

Koss-Olinger Consulting reported no remaining Co-Diagnostics position as of Q1 2025 after selling out during the quarter.
Koss-Olinger Consulting sold 1,937 Co-Diagnostics shares in Q1 2025, an estimated $44K.
Koss-Olinger Consulting first reported a position in Co-Diagnostics in Q4 2022 and held it in 8 quarters.
Koss-Olinger Consulting's Co-Diagnostics position peaked at $119K in Q3 2023.
38 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2025.

Based on Koss-Olinger Consulting's 13F filing for Q1 2025, filed 12 May 2025.